ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KZIA Kazia Therapeutics Ltd

0.405
0.0588 (16.98%)
20 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Kazia Therapeutics Ltd KZIA NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.0588 16.98% 0.405 10:00:00
Open Price Low Price High Price Close Price Previous Close
0.341 0.333406 0.407 0.376 0.3462
more quote information »

Recent News

Date Time Source Heading
21/3/202423:52PRNUSKazia Therapeutics licenses paxalisib to Sovargen for..
13/3/202423:00PRNUSKazia announces presentation of new data at AACR Annual..
22/2/202408:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/2/202401:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202423:30PRNUSKazia Therapeutics Reports Early Conclusion of Clinical..
15/2/202407:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202410:35EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
06/2/202408:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
19/1/202408:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202423:30PRNUSKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
13/1/202408:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/12/202309:26EDGAR2Form F-3 - Registration statement by foreign private issuers
07/12/202300:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/12/202310:02PRNUSKazia Therapeutics Announces Closing of $2 Million..
05/12/202308:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/12/202300:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/12/202300:00PRNUSKazia Therapeutics Announces $2 Million Registered Direct..
30/11/202308:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202308:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202323:01PRNUSKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE..
21/11/202323:30PRNUSKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS..
21/11/202308:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202308:30PRNUSKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
16/11/202301:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/11/202300:30PRNUSKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY..
10/11/202323:01PRNUSKAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS..
02/11/202307:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202322:01PRNUSKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING..
26/10/202322:56EDGAR2Form 20-F - Annual and transition report of foreign private..
23/10/202323:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202322:01PRNUSKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM..
14/10/202307:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202322:01PRNUSKazia announces voluntary delisting from ASX
11/10/202306:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202322:01PRNUSKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING..
29/9/202321:01PRNUSKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING..
29/9/202321:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202321:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/8/202321:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/7/202306:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/7/202321:00PRNUSKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA..
08/6/202321:00PRNUSKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO..
25/5/202321:01PRNUSKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE..

Your Recent History

Delayed Upgrade Clock